Clinical Edge Journal Scan

Better lifestyle index scores associated with improved mortality and disease recurrence in high-risk BC


 

Key clinical point: Adherence to the American Institute for Cancer Research and American Cancer Society’s lifestyle recommendations reduced the risk for disease recurrence and improved mortality in patients with high-risk breast cancer (BC).

Major finding: Patients in the highest vs lowest tertile of lifestyle index scores (LIS) experienced a 37% reduction in recurrence (hazard ratio [HR] 0.63; 95% CI 0.48-0.82) and those in the middle (HR 0.70; P = .03) and highest (HR 0.42; P < .001) vs lowest tertile of LIS had significant reductions in mortality.

Study details: Findings are from the prospective, observational, DELCaP (The Diet, Exercise, Lifestyles, and Cancer Prognosis) study including 1340 chemotherapy-naive women with high-risk stage I to III BC, of which the majority (65.3%) of women had hormone receptor-positive BC.

Disclosures: This study was supported by the US National Cancer Institute and The Breast Cancer Research Foundation, New York Some authors declared serving as members of independent data monitoring committees or receiving grants or personal fees from several sources.

Source: Cannioto RA et al. Adherence to cancer prevention lifestyle recommendations before, during, and 2 years after treatment for high-risk breast cancer. JAMA Netw Open. 2023;6(5):e2311673 (May 4). Doi: 10.1001/jamanetworkopen.2023.11673

Recommended Reading

New USPSTF draft suggests mammography start at 40, not 50
MDedge Hematology and Oncology
Number of cancer survivors with functional limitations doubled in 20 years
MDedge Hematology and Oncology
BMI has greater impact on survival in younger breast cancer patients
MDedge Hematology and Oncology
T-DXd for HER2-low BC: Analysis confirms adverse effects
MDedge Hematology and Oncology
Patritumab deruxtecan shows promise for breast cancer patients
MDedge Hematology and Oncology
Risk for breast cancer reduced after bariatric surgery
MDedge Hematology and Oncology
Atezolizumab is associated with enhanced response in triple-negative breast cancer
MDedge Hematology and Oncology
Genomic assay changes minds on HER2+ BC treatment
MDedge Hematology and Oncology
HR+ early BC patients could briefly interrupt endocrine therapy to attempt pregnancy
MDedge Hematology and Oncology
Anthracycline+taxane combo reduces BC recurrence more effectively than either drug alone
MDedge Hematology and Oncology